FuelCell Energy Inc vs Cassava Sciences Inc — how do they compare? FuelCell Energy Inc trades at $17.81 (market cap $1.62B), while Cassava Sciences Inc trades at $1.07 (market cap $53.14M). The key difference: FuelCell Energy Inc is far larger — about 30.5× Cassava Sciences Inc's market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | FLNA | |
|---|---|---|
Market Cap | $1.62B | $53.14M |
Sector | Industrials | Health |
52-Week High | $36.01 | $4.64 |
52-Week Low | $3.92 | $1.09 |
Enterprise Value | $1.47B | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $21.35, up 11.9% in the last 24 hours, reflecting high volatility amid recent news. The stock shows a neutral technical signal with bearish moving averages, while fundamentals reveal persistent losses with a net income margin of -132.41% in 2025 despite revenue growth to $158.16M. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225M stock offering that caused temporary dilution concerns.
The outlook is mixed: analyst consensus is balanced with a $20.75 price target, but continued cash burn and high valuation multiples pose risks. Opportunities lie in AI-driven data center demand, though profitability remains a key challenge for sustainable upside.
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Trailing returns across standard periods
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →